ArticleThe Journal of experimental medicine2003
Selective activation of the c-Jun NH2-terminal protein kinase signaling pathway by stimulatory KIR in the absence of KARAP/DAP12 in CD4+ T cells.
Article in The Journal of experimental medicine, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 73 citations in OpenAlex.
- KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma.Haematologica · 2023Article
- Membrane protein trafficking in the anti-tumor immune response: work of endosomal-lysosomal system.Cancer cell international · 2022Review
- Hallmarks of the aging T-cell system.The FEBS journal · 2021Review
- The immunology of rheumatoid arthritis.Nature immunology · 2021Review
- DAP12 impacts trafficking and surface stability of killer immunoglobulin-like receptors on natural killer cells.Journal of leukocyte biology · 2013Article
- The janus head of T cell aging - autoimmunity and immunodeficiency.Frontiers in immunology · 2013Article
- Immune aging and autoimmunity.Cellular and molecular life sciences : CMLS · 2012Review
- Natural killer cells and their role in rheumatoid arthritis: friend or foe?TheScientificWorldJournal · 2012Review
- Cytolytic CD4(+) T cells in viral immunity.Expert review of vaccines · 2010Review
- The tortoise and the hare: slowly evolving T-cell responses take hastily evolving KIR.Immunology · 2010Review
- Stimulatory and inhibitory killer Ig-like receptor molecules are expressed and functional on lupus T cells.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
- Pattern of DAP12 expression in leukocytes from both healthy and systemic lupus erythematosus patients.PloS one · 2009Article
- Age-related macular degeneration is associated with the HLA-Cw*0701 Genotype and the natural killer cell receptor AA haplotype.Investigative ophthalmology & visual science · 2008Article
- Umbilical cord blood T cells express multiple natural cytotoxicity receptors after IL-15 stimulation, but only NKp30 is functional.Journal of immunology (Baltimore, Md. : 1950) · 2008Article
- T-cell co-stimulatory pathways in autoimmunity.Arthritis research & therapy · 2008Review
- Associations of killer cell immunoglobulin-like receptor genes with complications of rheumatoid arthritis.Genes and immunity · 2007Article
- Uncoupling of T-cell effector functions by inhibitory killer immunoglobulin-like receptors.Blood · 2006Article
- Article
- TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque.The Journal of experimental medicine · 2006Article
- Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12.Nature immunology · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Activation of CD4(+) T cells is governed by interplay between stimulatory and inhibitory receptors; predominance of stimulatory signals favors autoimmune reactions. In patients with rheumatoid arthritis, expression of the critical costimulatory molecule, CD28, is frequently lost. Instead, CD4(+)CD28(null) T cells express killer immunoglobulin-like receptors (KIRs) with a preferential expression of the stimulatory receptor, CD158j. The frequency of CD4(+)CD28(null) T cells in rheumatoid arthritis (RA) correlates with the risk for more severe disease. Moreover, the KIR2DS2 gene, which encodes for CD158j, is a genetic risk factor for rheumatoid vasculitis. CD158j signals through the adaptor molecule, KARAP/DAP12, to positively regulate cytotoxic activity in NK cells. However, the majority of CD4(+)CD28(null) T cell clones lacked the expression of KARAP/DAP12. Despite the absence of KARAP/DAP12, CD158j was functional and augmented interferon-gamma production after T cell receptor stimulation. Cross-linking of CD158j resulted in selective phosphorylation of c-Jun NH(2)-terminal protein kinase (JNK) and its upstream kinase, MKK4 that led to the expression of ATF-2 and c-Jun, all in the absence of extracellular signal-regulated kinase (ERK)1/2 phosphorylation. Mutation of the lysine residue within the transmembrane domain of CD158j abolished JNK activation, suggesting that an alternate adaptor molecule was being used. CD4(+)CD28(null) T cells expressed DAP10 and inhibition of phosphatidylinositol 3-kinase, which acts downstream of DAP10, inhibited JNK activation; however, no interaction of DAP10 with CD158j could be detected. Our data suggest that CD158j in T cells functions as a costimulatory molecule through the JNK pathway independent of KARAP/DAP12 and DAP10. Costimulation by CD158j may contribute to the autoreactivity of CD4(+)CD28(null) T cells in RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.